The pressure to shorten delivery times and reduce costs for biologics such as mAbs are driving an evolution in the biomanufacturing space. Ironically, where we see almost daily innovation in production technologies, many of the methods used for biosafety testing are decades old. These traditional testing methods are often culture based and can take several weeks to produce the required result to allow for batch release. In this talk we will explore how new methods can be used to accelerate biosafety testing today, as well as how they can evolve to meet new manufacturing paradigms such as continuous processing and novel cell and gene therapy treatment modalities.
Adam Inche Ph.D.
Adam Inche joined the organization in 2015 to support biosafety testing. He is responsible for identifying forward trends in the biopharma industry related to biosafety services and is currently leading the development and launch of new rapid molecular testing methods. Adam was previously a product manager at Agilent where he was responsible for the development of applications on an automated electrophoresis platform. He received his doctorate in cancer cell biology from Oxford University in the United Kingdom and has recently completed an MBA at Edinburgh University.